APKN Airprotek International Inc. Corp.

Rafarma Has Agreed to Terms to Open its First Specialized Cannabis Spa in Europe

Rafarma Has Agreed to Terms to Open its First Specialized Cannabis Spa in Europe

Ljubljana, Slovenia, March 23, 2020 (GLOBE NEWSWIRE) -- RAFARMA PHARMACEUTICALS INC. “OTC:(RAFA)” - Rafarma Pharmaceuticals, Inc. is pleased to announce that it has successfully completed negotiations with Albopark Ocio SL (a New Heled Spain Holding company), which is the owner of the Hotel Albons in Girona, Spain. Under the agreed terms, Rafarma will open its first specialized spa in Europe. The spa will be located within the property of the Hotel Albons. The Spa will specialize in cannabis-based beauty and health products currently manufactured by Rafarma in Slovenia. The Company plans to duplicate its treatment protocols currently under development in Thailand in this first European spa, as well as other specialized spas to open throughout Europe. Opened in February of 2020, the Hotel Albons is a five-star property operated by CMC Hospitality. The Hotel Albons is in process to become part of a first-rate international brand. The company will commence preparation for the opening of the spa immediately, following the lifting of COVID-19 measures. To be ready for immediate opening following the lifting of measures, all spa materials will be supplied from the company headquarters in Ljubljana, Slovenia.

“Even though the world economy is going through incredible trials and tribulations caused by government-imposed restrictions to prevent the spread of Coronavirus, the current situation presents companies like Rafarma with incredible opportunities based on its economies of scale--we are able to continue to expand operations with the knowledge that the demand for cannabis continues to rise. We can also continue to pursue European acquisition targets during this time, including active negotiations with a Croatian company and a Macedonian company. We believe our entrance into the Spanish market and the acquisition of one or both of these companies in the Balkans, will be additional milestones in our plan to be a global provider of cannabis-based products, spas and other related cannabis ventures, with large operations on multiple continents”, comments company CEO Vladimir Dolgolenko.

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For more information contact:

RAFARMA

(307) 429-2029

EN
23/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Airprotek International Inc. Corp.

 PRESS RELEASE

Rafarma pharmaceutical updates: agreements with Shri Lanka pharmaceuti...

Rafarma pharmaceutical updates: agreements with Shri Lanka pharmaceutical company Kelun Lifesciences (Pvt) Ltd and El Salvador University Wyoming, USA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - We are pleased to announce that Rapharma and its CEO Raivo Unt have entered into a preliminary agreement with Kelun Lifesciences (Pvt) Ltd, a pharmaceutical company based in Sri Lanka, on 17 November 2023. It is Sri Lanka's first and only pharmaceutical manufacturing facility for sterile liquid injections and infusions. The headquarters of the company is based in Kandy...

 PRESS RELEASE

Rafarma Pharmaceutical news update

Rafarma Pharmaceutical news update Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet procedures required to comply with GAAP auditing standards. Due to the changed geopolitical situation, the company was unable to complete the review of some of the assets that were set for audit consolidation, namely Kraspharma and Bebig. The Company will continue to provide its shareholders with regular unaudited financial statements of Kraspharma and Bebig. Onc...

 PRESS RELEASE

Rafarma Pharmaceuticals strengthens its position in Central Asia

Rafarma Pharmaceuticals strengthens its position in Central Asia Nicosia, Cyprus, April 29, 2022 (GLOBE NEWSWIRE) -- Representatives of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) visited Uzbekistan and discussed the prospects for the company's development in the territory of the innovative research and production pharmaceutical cluster "Tashkent Pharma Park". Rafarma Pharmaceuticals is not new to the Central Asian market, the company has been operating there for a long time and plans to increase its presence by creating local production. Over the next three years, the company plans to bui...

 PRESS RELEASE

Rafarma’s Slavich Noya Technology Division Expands Printing Production

Rafarma’s Slavich Noya Technology Division Expands Printing Production Nicosia, Cyprus, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) Slavich Noya Technology, part of the Rafarma Pharmaceuticals group of companies, is expanding its production capabilities as it is in active negotiations for the acquisition of two machines from BOBST (), one of the world’s leading suppliers of substrate processing, printing and converting equipment and services for the label, flexible packaging, folding carton and corrugated board industries. Slavich Noya Technology will great...

 PRESS RELEASE

RAFA Enters into Negotiations with JINR for Ultra-Cutting Edge Nuclear...

RAFA Enters into Negotiations with JINR for Ultra-Cutting Edge Nuclear Research Nicosia, Cyprus, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is currently negotiating with the Joint Institute for Nuclear Research (JINR), an international intergovernmental scientific organization established by eleven founding countries in 1956 and registered by the United Nations. The purpose of the current negotiations is the development and implementation of Rafarma Pharmaceuticals’ projects related to nuclear medicine technologies, radiopharmaceuticals, radiotherapy and pr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch